39 recommendations for Canada's life sciences sector.
None costed. None with an estimate of what it returns.
So I estimated them — on two ledgers, kept separate. What the treasury gets back. What firms and households get.
Four quadrants.
Both ledgers pay. Data and innovation. Vital, the health data platform going national, is the only item in the 39 that sits here. The other thing that belongs here isn't in the report: a domestic ARPA-H. Canada already runs one — in the international development envelope.
Economic only. $1B of public risk capital creates ~$7.8B of enterprise value. Canadians keep about $1B of it. In rounds above $50M, all-Canadian syndicates supply 12.7% of the dollars. Value created here, owned somewhere else.
Fiscal only. AI-enabled service delivery across the health system. Vendor-neutral — the treasury gains wherever the innovation is made.
Neither. Most of the regulatory recommendations. Cheap, so they'll be attractive. Fine, unless they crowd out what carries real weight.
Technical paper and workbook annexed, so you can check the arithmetic or run it on your own country's strategy.
Link in first reply